Relacorilant in Combination With Different Treatment Regimens in Patients With Gynecological Cancers
A phase 2 trial of Relacorilant and Bevacizumab in ovarian cancer and endometrial cancer, run by Corcept Therapeutics, now recruiting.
Overview
Relacorilant in Combination With Different Treatment Regimens in Patients With Gynecological Cancers is a phase 2 interventional study registered as NCT06906341 by Corcept Therapeutics, with 270 participants planned, started 2025-04-11 and due to reach its primary completion in 2026-08. Interventions recorded: Relacorilant 150 mg once daily (QD), Nab-paclitaxel 80 mg/m^2 and Bevacizumab 10 mg/kg.
Similar pages
not linked directly; found by shared links- TrialRelacorilant With Nab-Paclitaxel and Gemcitabine in Patients With Metastatic Pancreatic Adenocarcinoma
Shares Relacorilant, Corcept Therapeutics and the tag pipeline.
- TrialTwo Part Study of Nenocorilant Combined With Nivolumab in Patients With Advanced Solid Malignancies
Shares Corcept Therapeutics and the tag pipeline.
- TrialA Study of DM002 in Patients With Advanced Solid Tumors
Shares Endometrial cancer, Ovarian cancer and the tag pipeline.
- TrialA Study of PARG Inhibitor ETX-19477 in Patients With Advanced Solid Malignancies
Shares Endometrial cancer, Ovarian cancer and the tag pipeline.
- TrialA Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity of INV-6452 in Adult Patients With Hormone Receptor Positive, Human Epidermal Growth Factor Receptor 2 Negative (HR+/HER2-) Advanced/Metastatic Breast Cancer or Locally Advanced/Metastatic Solid Tumor
Shares Endometrial cancer, Ovarian cancer and the tag pipeline.
- TrialA Study of Disitamab Vedotin in Previously Treated Solid Tumors That Express HER2
Shares Endometrial cancer, Ovarian cancer and the tag pipeline.
- TrialA Phase I/II Study of VLS-1488 in Subjects With Advanced Cancer
Shares Endometrial cancer, Ovarian cancer and the tag pipeline.
- TrialA Study of Emiltatug Ledadotin (Emi-Le) in Participants With Solid Tumors
Shares Endometrial cancer, Ovarian cancer and the tag pipeline.